<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01268046</url>
  </required_header>
  <id_info>
    <org_study_id>2009P-002311</org_study_id>
    <secondary_id>R01AG013241</secondary_id>
    <nct_id>NCT01268046</nct_id>
  </id_info>
  <brief_title>Aging and Estrogen on Cortical Function</brief_title>
  <official_title>The Effect of Low Dose Estrogen on Cortical Function as a Function of Age in Postmenopausal Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will focus on how estrogen affects parts of the brain associated with memory and
      how the effect of estrogen is altered with aging in postmenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The broad goal of this proposal is to determine the effect of aging on areas of the brain
      whose function is impacted by gonadal steroids in women. The overarching hypothesis is that
      aging differentially alters the effects of estrogen on the brain. Our preliminary data
      indicated that aging alters the effect of estrogen on brain regions involved in cognition and
      thus, the current study focused on the impact of aging on functional changes induced by
      estrogen in cortical and subcortical areas associated with verbal working memory and
      declarative/episodic memory.

      As our model, we will use women in whom the absence of gonadal function makes it possible to
      control the duration and amount of estrogen exposure, specifically postmenopausal women who
      are younger (45-55) or older (65-80) who receive either oral or transdermal estradiol to
      achieve premenopausal early follicular phase estradiol levels.. We evaluate the effects of
      low dose estrogen exposure at 48 hr and 1 month to determine whether the short-term changes
      in brain regions involved in cognition with low dose estrogen exposure seen in our
      preliminary studies are confirmed and whether changes with short-term estrogen exposure
      persist with more prolonged exposure, a finding that would have enormous clinical relevance.
      These studies, using sophisticated neuroimaging tools (structural and functional magnetic
      resonance imaging [MRI] and [18F] 2-fluoro-2-deoxy-D-glucose positron emission tomography
      [FDG-PET]), provide a unique window into the brain in women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2009</start_date>
  <completion_date type="Actual">December 2, 2013</completion_date>
  <primary_completion_date type="Actual">December 2, 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Each participant was randomized to placebo or estrogen using a block randomized design by age group</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization was performed by the Research Pharmacy and the investigative team was blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Magnetic Resonance Imaging (fMRI) Changes in Response to Estrogen and Aging - Dorsolateral Pre-frontal Cortex (DLPFC)</measure>
    <time_frame>baseline to 1 month</time_frame>
    <description>Change in extracted beta coefficients of the blood oxygen level dependent (BOLD) signal response to a cognitive task (N-back) in the DLPFC (x,y,z coordinates = -34 44 16) from baseline to 1 month as a function of aging and estrogen (young vs older and estrogen vs placebo). A positive change indicates an increase in oxygen utilization (inferring increased neuronal functioning) between baseline and treatment during the cognitive task, while a negative change indicates a decrease in oxygen utilization between baseline and treatment during the cognitive task.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Memory Loss</condition>
  <condition>Cognitive Changes</condition>
  <condition>Postmenopausal Symptoms</condition>
  <arm_group>
    <arm_group_label>Young postmenopausal women - estrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>transdermal estrogen patch OR estradiol oral capsule for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Older postmenopausal women - estrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>transdermal estrogen patch OR estradiol oral capsule for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Young postmenopausal women - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>transdermal placebo patch for 1 month or placebo oral capsule for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Older postmenopausal women - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>transdermal placebo patch for 1 month or placebo oral capsule for 1 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol oral capsule</intervention_name>
    <description>1 oral capsule (1 mg estradiol) administered daily for one month</description>
    <arm_group_label>Older postmenopausal women - estrogen</arm_group_label>
    <arm_group_label>Young postmenopausal women - estrogen</arm_group_label>
    <other_name>Micronized Estradiol</other_name>
    <other_name>Estradiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>transderman estrogen patch</intervention_name>
    <description>transdermal estrogen patch (50 mcg/day) for one month</description>
    <arm_group_label>Older postmenopausal women - estrogen</arm_group_label>
    <arm_group_label>Young postmenopausal women - estrogen</arm_group_label>
    <other_name>Climara</other_name>
    <other_name>Estraderm</other_name>
    <other_name>Estrogen patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trasdermal placebo patch</intervention_name>
    <description>transdermal placebo patch with patch change every 84 hr for one month</description>
    <arm_group_label>Older postmenopausal women - placebo</arm_group_label>
    <arm_group_label>Young postmenopausal women - placebo</arm_group_label>
    <other_name>Placebo patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo oral capsule</intervention_name>
    <description>placebo oral capsule administered daily for one month.</description>
    <arm_group_label>Older postmenopausal women - placebo</arm_group_label>
    <arm_group_label>Young postmenopausal women - placebo</arm_group_label>
    <other_name>Placebo capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. young postmenopausal (age 45-55) or older (age 65-80) postmenopausal women

          2. otherwise healthy, non-obese women with normal blood pressure and a history of normal
             menopause, defined by the absence of menses for at least 12 months

          3. prescription hormone replacement treatment discontinued at least 3 months before study

          4. Normal or corrected normal vision

          5. Intelligence quotient (IQ) &gt; 70 on the Wechsler Adult Reading Test (WTAR)*

          6. Absence of Mild Cognitive Impairment (MCI) and depression on the Mini Mental State
             Examination (MMSE)** and Beck Depression Inventory II (BDI-II).***

          7. Normal mammogram or breast MRI within the past 2 years

        Exclusion Criteria

          1. On gonadal hormone replacement medication, herbal supplements and/or over the counter
             menopause treatment within three months of study

          2. History of radiotherapy or chemotherapy.

          3. Absolute contraindications to the use of physiologic replacement doses of estrogen
             and/or history of coronary artery disease

          4. History of breast cancer, blood clot, pulmonary embolus, hypercoagulability and
             stroke.

          5. On centrally acting medications

          6. History of head trauma and/or neurologic disorder

          7. Contraindication to MRI (eg. metal implants) or PET imaging (eg. PET imaging studies
             in the previous 12 months)

          8. Concurrent participation in research studies involving medications and/or PET scans.

          9. Left handedness.

         10. Current breast lump(s) or family/genetic history of breast cancer in younger women (&lt;
             40 years old).

         11. Current smoking
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet E Hall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reproductive Endocrine Unit, Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>December 28, 2010</study_first_submitted>
  <study_first_submitted_qc>December 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2010</study_first_posted>
  <results_first_submitted>April 18, 2017</results_first_submitted>
  <results_first_submitted_qc>July 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 22, 2018</results_first_posted>
  <last_update_submitted>July 24, 2018</last_update_submitted>
  <last_update_submitted_qc>July 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Janet E. Hall, MD</investigator_full_name>
    <investigator_title>Associate Physician</investigator_title>
  </responsible_party>
  <keyword>aging</keyword>
  <keyword>postmenopausal women</keyword>
  <keyword>estrogen</keyword>
  <keyword>memory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified information will be made available on request to the PI once the primary data analysis has been published.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>From time of publication of initial 2 manuscripts (December 2019) for 5 years</ipd_time_frame>
    <ipd_access_criteria>Academic investigator with funding for analysis, approval of PI</ipd_access_criteria>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Young Postmenopausal Women - Estrogen</title>
          <description>1 oral capsule (1 mg estradiol) administered daily for one month OR 1 transdermal estrogen patch (50 mcg/day) with patch change every 84 hr for one month in younger postmenopausal women</description>
        </group>
        <group group_id="P2">
          <title>Older Postmenopausal Women - Estrogen</title>
          <description>1 oral capsule (1 mg estradiol) administered daily for one month OR 1 transdermal estrogen patch (50 mcg/day) with patch change every 84 hr for one month in older postmenopausal women</description>
        </group>
        <group group_id="P3">
          <title>Young Postmenopausal Women - Placebo</title>
          <description>1 placebo capsule administered daily for one month OR 1 placebo patch with patch change every 84 hr for one month in younger postmenopausal women</description>
        </group>
        <group group_id="P4">
          <title>Older Postmenopausal Women - Placebo</title>
          <description>1 placebo capsule administered daily for one month OR 1 placebo patch with patch change every 84 hr for one month in older postmenopausal women</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Young Postmenopausal Women - Estrogen</title>
          <description>1 oral capsule (1 mg estradiol) administered daily for one month OR 1 transdermal estrogen patch (50 mcg/day) with patch change every 84 hr for one month in younger postmenopausal women</description>
        </group>
        <group group_id="B2">
          <title>Older Postmenopausal Women - Estrogen</title>
          <description>1 oral capsule (1 mg estradiol) administered daily for one month OR 1 transdermal estrogen patch (50 mcg/day) with patch change every 84 hr for one month in older postmenopausal women</description>
        </group>
        <group group_id="B3">
          <title>Younger Postmenopausal Women - Placebo</title>
          <description>1 placebo capsule administered daily for one month OR 1 placebo patch with patch change every 84 hr for one month in younger postmenopausal women</description>
        </group>
        <group group_id="B4">
          <title>Older Postmenopausal Women - Placebo</title>
          <description>1 placebo capsule administered daily for one month OR 1 placebo patch with patch change every 84 hr for one month in older postmenopausal women</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.9" spread="0.7"/>
                    <measurement group_id="B2" value="69.8" spread="1.1"/>
                    <measurement group_id="B3" value="51.1" spread="1.0"/>
                    <measurement group_id="B4" value="71.4" spread="1.1"/>
                    <measurement group_id="B5" value="61.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Functional Magnetic Resonance Imaging (fMRI) Changes in Response to Estrogen and Aging - Dorsolateral Pre-frontal Cortex (DLPFC)</title>
        <description>Change in extracted beta coefficients of the blood oxygen level dependent (BOLD) signal response to a cognitive task (N-back) in the DLPFC (x,y,z coordinates = -34 44 16) from baseline to 1 month as a function of aging and estrogen (young vs older and estrogen vs placebo). A positive change indicates an increase in oxygen utilization (inferring increased neuronal functioning) between baseline and treatment during the cognitive task, while a negative change indicates a decrease in oxygen utilization between baseline and treatment during the cognitive task.</description>
        <time_frame>baseline to 1 month</time_frame>
        <population>all young and older postmenopausal women who completed one month of placebo or estrogen and in whom structural and functional MRI data were of significant quality for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Young Postmenopausal Women - Estrogen</title>
            <description>1 oral capsule (1 mg estradiol) administered daily for one month OR 1 transdermal estrogen patch (50 mcg/day) with patch change every 84 hr for one month in younger postmenopausal women</description>
          </group>
          <group group_id="O2">
            <title>Older Postmenopausal Women - Estrogen</title>
            <description>1 oral capsule (1 mg estradiol) administered daily for one month OR 1 transdermal estrogen patch (50 mcg/day) with patch change every 84 hr for one month in older postmenopausal women</description>
          </group>
          <group group_id="O3">
            <title>Young Postmenopausal Women - Placebo</title>
            <description>1 placebo capsule administered daily for one month OR 1 transdermal placebo patch with patch change every 84 hr for one month in younger postmenopausal women</description>
          </group>
          <group group_id="O4">
            <title>Older Postmenopausal Women - Placebo</title>
            <description>1 placebo capsule administered daily for one month OR 1 transdermal placebo patch with patch change every 84 hr for one month in younger postmenopausal women</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Magnetic Resonance Imaging (fMRI) Changes in Response to Estrogen and Aging - Dorsolateral Pre-frontal Cortex (DLPFC)</title>
          <description>Change in extracted beta coefficients of the blood oxygen level dependent (BOLD) signal response to a cognitive task (N-back) in the DLPFC (x,y,z coordinates = -34 44 16) from baseline to 1 month as a function of aging and estrogen (young vs older and estrogen vs placebo). A positive change indicates an increase in oxygen utilization (inferring increased neuronal functioning) between baseline and treatment during the cognitive task, while a negative change indicates a decrease in oxygen utilization between baseline and treatment during the cognitive task.</description>
          <population>all young and older postmenopausal women who completed one month of placebo or estrogen and in whom structural and functional MRI data were of significant quality for analysis.</population>
          <units>linear beta extractions</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="455.8" spread="164.3"/>
                    <measurement group_id="O2" value="-214.4" spread="90.1"/>
                    <measurement group_id="O3" value="-348.1" spread="215.3"/>
                    <measurement group_id="O4" value="90.1" spread="215.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Young Postmenopausal Women - Estrogen</title>
          <description>1 oral capsule (1 mg estradiol) administered daily for one month OR : 1 transdermal estrogen patch (50 mcg/day) with patch change every 84 hr for one month in younger postmenopausal women</description>
        </group>
        <group group_id="E2">
          <title>Older Postmenopausal Women - Estrogen</title>
          <description>1 oral capsule (1 mg estradiol) administered daily for one month OR : 1 transdermal estrogen patch (50 mcg/day) with patch change every 84 hr for one month in older postmenopausal women</description>
        </group>
        <group group_id="E3">
          <title>Young Postmenopausal Women - Placebo</title>
          <description>1 placebo capsule administered daily for one month OR 1 transdermal placebo patch with patch change every 84 hr for one month in younger postmenopausal women</description>
        </group>
        <group group_id="E4">
          <title>Older Postmenopausal Women - Placebo</title>
          <description>1 placebo capsule administered daily for one month OR 1 transdermal placebo patch with patch change every 84 hr for one month in younger postmenopausal women</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>twisted knee</sub_title>
                <description>Participant slipped on wet floor after consent and screening but before any study procedures initiated.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <description>Chronic back condition aggravated during MRI due to positioning.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>light headed</sub_title>
                <description>Brief period of dizziness one week after completing all procedures. Resolved and no abnormalities noted on clinical MRI.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <description>Experience anxiety in magnet on 1/3 occasions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>urticaria</sub_title>
                <description>reported hives 9 days after all study procedures completed</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Janet Hall, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-877-1112</phone>
      <email>janet.hall@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

